Global DTaP and Tdap Vaccines Market Insights, Forecast to 2025

2 Global DTaP and Tdap Vaccines Quarterly Market Size Analysis

• 2.1 DTaP and Tdap Vaccines Business Impact Assessment - COVID-19
  • 2.1.1 Global DTaP and Tdap Vaccines Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global DTaP and Tdap Vaccines Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global DTaP and Tdap Vaccines Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global DTaP and Tdap Vaccines Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global DTaP and Tdap Vaccines Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers DTaP and Tdap Vaccines Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into DTaP and Tdap Vaccines Market
• 3.5 Key Manufacturers DTaP and Tdap Vaccines Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on DTaP and Tdap Vaccines Segments, By Type

• 4.1 Introduction
  • 1.4.1 DTaP
  • 1.4.2 Td
  • 1.4.3 Tdap
• 4.2 By Type, Global DTaP and Tdap Vaccines Market Size, 2019-2021
  • 4.2.1 By Type, Global DTaP and Tdap Vaccines Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global DTaP and Tdap Vaccines Price, 2020-2021

5 Impact of Covid-19 on DTaP and Tdap Vaccines Segments, By Application

• 5.1 Overview
  • 5.5.1 Adult
  • 5.5.2 Pediatric
• 5.2 By Application, Global DTaP and Tdap Vaccines Market Size, 2019-2021
  • 5.2.1 By Application, Global DTaP and Tdap Vaccines Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global DTaP and Tdap Vaccines Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Sanofi Pasteur
  • 7.1.1 Sanofi Pasteur Business Overview
  • 7.1.2 Sanofi Pasteur DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Product Introduction
  • 7.1.4 Sanofi Pasteur Response to COVID-19 and Related Developments
• 7.2 GlaxoSmithKline
  • 7.2.1 GlaxoSmithKline Business Overview
  • 7.2.2 GlaxoSmithKline DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Product Introduction
  • 7.2.4 GlaxoSmithKline Response to COVID-19 and Related Developments
• 7.3 Protein Sciences Corporation
  • 7.3.1 Protein Sciences Corporation Business Overview
  • 7.3.2 Protein Sciences Corporation DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Product Introduction
  • 7.3.4 Protein Sciences Corporation Response to COVID-19 and Related Developments
• 7.4 Novartis AG
  • 7.4.1 Novartis AG Business Overview
  • 7.4.2 Novartis AG DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.4.3 Novartis AG DTaP and Tdap Vaccines Product Introduction
  • 7.4.4 Novartis AG Response to COVID-19 and Related Developments
• 7.5 Seqirus
  • 7.5.1 Seqirus Business Overview
  • 7.5.2 Seqirus DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.5.3 Seqirus DTaP and Tdap Vaccines Product Introduction
  • 7.5.4 Seqirus Response to COVID-19 and Related Developments
• 7.6 Merck Sharp & Dohme Corp
  • 7.6.1 Merck Sharp & Dohme Corp Business Overview
  • 7.6.2 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Introduction
  • 7.6.4 Merck Sharp & Dohme Corp Response to COVID-19 and Related Developments
• 7.7 Astellas Pharma US, Inc
  • 7.7.1 Astellas Pharma US, Inc Business Overview
  • 7.7.2 Astellas Pharma US, Inc DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Introduction
  • 7.7.4 Astellas Pharma US, Inc Response to COVID-19 and Related Developments
• 7.8 Pfizer Inc
  • 7.8.1 Pfizer Inc Business Overview
  • 7.8.2 Pfizer Inc DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.8.3 Pfizer Inc DTaP and Tdap Vaccines Product Introduction
  • 7.8.4 Pfizer Inc Response to COVID-19 and Related Developments
• 7.9 Johnson & Johnson
  • 7.9.1 Johnson & Johnson Business Overview
  • 7.9.2 Johnson & Johnson DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.9.3 Johnson & Johnson DTaP and Tdap Vaccines Product Introduction
  • 7.9.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.10 Lanzhou Institute of Biological Products Co., Ltd
  • 7.10.1 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  • 7.10.2 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Introduction
  • 7.10.4 Lanzhou Institute of Biological Products Co., Ltd Response to COVID-19 and Related Developments
• 7.11 AstraZeneca
  • 7.11.1 AstraZeneca Business Overview
  • 7.11.2 AstraZeneca DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.11.3 AstraZeneca DTaP and Tdap Vaccines Product Introduction
  • 7.11.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.12 Emergent BioSolutions Inc
  • 7.12.1 Emergent BioSolutions Inc Business Overview
  • 7.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Quarterly Production and Revenue, 2020
  • 7.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Introduction
  • 7.12.4 Emergent BioSolutions Inc Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 DTaP and Tdap Vaccines Supply Chain Analysis
  • 8.1.1 DTaP and Tdap Vaccines Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on DTaP and Tdap Vaccines Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 DTaP and Tdap Vaccines Distribution Channels
  • 8.2.2 Covid-19 Impact on DTaP and Tdap Vaccines Distribution Channels
  • 8.2.3 DTaP and Tdap Vaccines Distributors
• 8.3 DTaP and Tdap Vaccines Customers

9 Key Findings

10 Appendix

• 10.1 About Us